Document Detail


Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
MedLine Citation:
PMID:  9490238     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Although the stratification of patients with myocardial infarction into ECG subsets based on the presence or absence of new Q waves has important clinical and prognostic utility, systematic evaluation of the impact of thrombolytic therapy on the subsequent development and prognosis of non-Q-wave infarction has been limited to date. METHODS AND RESULTS: We examined 12-lead ECG, coronary anatomy, left ventricular function, and mortality among 2046 patients with ST-segment elevation infarction from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries angiographic subset to gain further insight into the pathophysiology and prognosis of Q- versus non-Q-wave infarction in the thrombolytic era. Non-Q-wave infarction developed in 409 patients (20%) after thrombolytic therapy. Compared with Q-wave patients, non-Q-wave patients were more likely to present with lesser ST-segment elevation in a nonanterior location. The infarct-related artery in non-Q-wave patients was more likely to be nonanterior (67% versus 58%, P=.012) and distally located (33% versus 39%, P=.021). Early (90-minute, 77% versus 65%, P=.001) and complete (54% versus 44%, P<.001) infarct-related artery patency was greater among the non-Q-wave group. Non-Q-wave patients had better global (ejection fraction, 66% versus 57%; P<.0001) and regional left ventricular function (10 versus 24 abnormal chords, P=.0001). In-hospital, 30-day, 1-year, and 2-year (6.3% versus 10.1%, P=.02) mortality rates were lower among non-Q-wave patients. CONCLUSIONS: The excellent prognosis among the subgroup of patients who develop non-Q-wave infarction after thrombolysis is related to early, complete, and sustained infarct-related artery patency with resultant limitation of left ventricular infarction and dysfunction.
Authors:
S G Goodman; A Langer; A M Ross; N M Wildermann; A Barbagelata; E B Sgarbossa; G S Wagner; C B Granger; R M Califf; E J Topol; M L Simoons; P W Armstrong
Related Documents :
7732978 - Use of p-wave-triggered, p-wave signal-averaged electrocardiogram to predict atrial fib...
10051038 - Electrocardiographic evaluation of broilers following unilateral occlusion of an extrap...
2030548 - Clinical significance of abnormal q wave disappearance in acute transmural myocardial i...
20703898 - Frontal plane vectorcardiograms: theory and graphics visualization of cardiac health st...
15133408 - Effect of drug therapy for heart failure on quality of life.
18190988 - Relation of left atrial blood stasis to clinical risk factors in atrial fibrillation.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation     Volume:  97     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-03-04     Completed Date:  1998-03-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  444-50     Citation Subset:  AIM; IM    
Affiliation:
The Terrence Donnelly Heart Centre, Division of Cardiology, St Michael's Hospital, University of Toronto, Ontario, Canada. goodmans@smh.toronto.on.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Coronary Angiography
Electrocardiography
Female
Fibrinolytic Agents / therapeutic use*
Heart Catheterization
Humans
Male
Middle Aged
Myocardial Infarction / drug therapy*,  physiopathology
Prognosis
Streptokinase / therapeutic use*
Thrombolytic Therapy*
Tissue Plasminogen Activator / therapeutic use*
Treatment Outcome
Ventricular Function, Left / drug effects
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular d...
Next Document:  Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. ...